MolecularHealth demonstrates Personalized Cancer Therapy Solutions at 2013 CeBIT Treatment Decision Support Solutions presented at MolecularHealth Partner, SAP AG, Booth
NEW YORK and HEIDELBERG, Germany, March 5, 2013 /PRNewswire/ -- MolecularHealth, a leader in clinico-molecular informatics™, today announced that the company will demonstrate their latest capabilities at CeBIT 2013, taking place in Hannover, Germany March 5-9. The company is advancing precision medicine by providing decision support solutions that translate patient-specific molecular and genomic data, treatment-relevant clinical history, and published scientific evidence in combination with mechanism-based therapy knowledge into safer, more effective drug choices. MolecularHealth's Personalized Cancer Therapy Solutions offer health providers and patients an integrated service that unlocks evidence-based treatment strategies from the genome, patient clinical history and extensive knowledge about drug therapy mechanisms of action.
Benefitting from the unprecedented speed and performance of the SAP HANA® platform, the offering aims to tackle the challenges of immense bodies of disparate medical, biological and drug data, manual and time consuming analysis, and the increasingly complex treatment paradigms affecting pathologists, oncologists and patients and their families. MolecularHealth will demonstrate its Molecular Analysis of Side Effects™ (MASE) and Oncology Decision Support capabilities in the SAP booth, Hall 4 Stand C04. These capabilities reflect SAP's recent entry with the SAP HANA platform and partners such as MolecularHealth into the increasingly accessible field of genomics and next generation sequencing-driven clinical decision support.
MolecularHealth, a clinico-molecular informatics company offering mechanism-based drug safety and Personalized Cancer Therapy Solutions, is advancing precision medicine by translating patient-specific molecular and genomic data, clinical history, drug knowledge and published scientific and medical evidence into safer, more effective drug choices for patients. The company's solutions range from a next generation drug safety assessment and prediction tool that analyzes the molecular basis of adverse events to a treatment decision support offering that informs evidence-based treatment strategies for cancer patients. MolecularHealth's collaborators include the University of Texas MD Anderson Cancer Center, SAP AG, and the U.S. Food and Drug Administration (FDA). Visit www.molecularhealth.com.
© 2013 The MolecularHealth name and logo are trademarks of Molecular Health AG.
SAP, SAP HANA, and all SAP logos are trademarks or registered trademarks of SAP AG in Germany and in several other countries.
All other product and service names mentioned are the trademarks of their respective companies.